Handelsavisen
prelaunch
Companies Healthcare 042520.KQ
04
042520.KQ KOSDAQ Medical Equipment, Supplies & Distribution

042520.Kq

$25 950,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
369,6B KRW
P/E
EV / Rev
Div yield
Op margin
-28,8 %
ROE
-93,0 %
Net margin
-34,9 %
Debt / equity
1,28
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.

Business. The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target64 000,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
64 000,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
-93,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 042520.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 042520.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 1.28, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.69, suggesting limited short-term liquidity. The company's price-to-book ratio is 13.1, which is significantly higher than typical industry norms, reflecting a premium valuation relative to its book value. The company's return on equity is -0.93, and its return on assets is -0.25, both of which are negative and indicate poor profitability and asset utilization.

    The company's profitability is weak, with a net loss of 31,341,350,200 KRW and an operating loss of 25,890,557,570 KRW. Its gross profit margin is 57.4%, which is relatively high but insufficient to offset the operating and net losses. The company's free cash flow is negative at -29,177,299,300 KRW, indicating that it is not generating sufficient cash from operations to fund its capital expenditures and other operational needs.

    The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification. The company's operations are primarily based in its home market, and there is no indication of substantial international revenue streams. This concentration increases the company's exposure to local economic and regulatory risks.

    The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The company's capital expenditures are negative, suggesting a reduction in investment in long-term assets. The company's operating cash flow is positive at 318,338,520 KRW, but this is insufficient to cover its free cash flow deficit. The company's future growth will depend on its ability to improve profitability and manage its debt burden.

    The company faces several risk factors, including a high debt-to-equity ratio and a negative free cash flow, which could lead to liquidity constraints. The company's dilution potential is assessed as low, but its negative net cash position after subtracting total debt is a key flag. The company's risk assessment indicates that it is not currently facing significant dilution pressure, but its financial position remains vulnerable.

    Recent events, as disclosed in the company's financial statements, include a significant operating and net loss, which may have impacted investor sentiment. The company's price target from analysts is 64,000 KRW, with a mean recommendation of 1.00, indicating a strong buy rating. However, the company's financial performance and risk profile suggest that investors should exercise caution.

    Key takeaways
    • The company has a high debt-to-equity ratio of 1.28, indicating a moderate reliance on debt financing.
    • The company's profitability is weak, with a net loss of 31,341,350,200 KRW and an operating loss of 25,890,557,570 KRW.
    • The company's revenue is concentrated in a single segment, increasing its exposure to local economic and regulatory risks.
    • The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year.
    • The company faces several risk factors, including a high debt-to-equity ratio and a negative free cash flow, which could lead to liquidity constraints.
    • **margin_outlook_rationale**: The company's gross profit margin is 57.4%, but this is insufficient to offset the operating and net losses, indicating a negative margin outlook.
    • **rd_outlook_rationale**: The company's capital expenditures are negative, suggesting a reduction in investment in long-term assets, which may impact future research and development efforts.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $25 950,00
    Market cap
    $441.48B
    Enterprise value
    $478.12B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    1501.9x
    P / B
    13.1x
    P / Tangible book
    13.1x
    Tangible book
    $33.70B
    Net cash
    -$36.64B
    Current ratio
    0.7
    Debt / equity
    1.3
    ROA
    -24.8%
    ROE
    -93.0%
    Cash conversion
    -1.0%
    CapEx / revenue
    -2.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    827,95
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-04 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate827,95
    Revenueno estimateno estimate137,2B KRW
    Operating incomeno estimateno estimate15,1B KRW
    Full-year consensus mean (period as reported by source) · consensus in KRW. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy1
    Buy0
    Hold0
    Sell0
    Strong sell0
    12-month price target$64 000,00 · Median $64 000,00
    Low $64 000,00High $64 000,00
    Operating income · consensus15,1B KRW
    EPS surprise
    −391,4 %
    reported vs consensus · miss
    Revenue surprise
    −34,6 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$64 000,00
    Mean$64 000,00
    Median$64 000,00
    High$64 000,00
    Spot$25 950,00
    +146.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-28,8 %Bottom quartile
    Net Margin-34,9 %Bottom quartile
    ROE-93,0 %Bottom quartile
    Capex / Rev-2,0 %Above P75
    D/E1,28Bottom quartile
    Cash Conv-0,01Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • 042520.KQ Market data — financials · 2026-05-26
    • Hans Biomed Corp Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    042520.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage